SPRAVATO
SPRAVATO® (esketamine) is an FDA-approved nasal spray that can help people living with depression who have tried medications and are still struggling with symptoms. It’s a specialized treatment option to consider for yourself or a loved one that is covered by major insurance and overseen by our board-certified behavioral health providers.
How SPRAVATO works
Rosecrance is a Risk Evaluation and Mitigation Strategy (REMS)-certified provider of SPRAVATO for difficult-to-treat depression (treatment-resistant depression) and major depressive disorder (MDD) with suicidal thoughts or actions. SPRAVATO is appropriate for people ages 18 and older with these conditions who have tried a minimum of two medications without significant improvement.
SPRAVATO targets receptors in the brain that are responsible for the way certain mood-regulating signals are transmitted between cells. Potential benefits include mood stabilization and reduction of suicidal thoughts. SPRAVATO is taken with an oral antidepressant.
Patients administer SPRAVATO nasal spray themselves under the supervision of a board-certified behavioral health provider. Afterward, they are observed for two hours to monitor vital signs and treatment progress. Patients attend treatment sessions one to two times weekly in our comfortable, therapeutic space, and will require transportation following sessions.
The treatment is covered by most major insurance plans, including Medicare, and offers a special savings program that helps with treatment costs for commercially insured patients. We will work with you to verify insurance coverage and secure any authorization needed; we also offer self-payment options.
View all SPRAVATO locations within Rosecrance Therapies
Rockford, IL & Surrounding Areas
We offer a complimentary consultation to discuss treatment options with our team and offer SPRAVATO at the locations listed above.
Minimal side effects and risks
SPRAVATO can cause side effects such as sleepiness (sedation), dizziness, or feeling disconnected (dissociation). Treatment is only delivered at healthcare providers such as Rosecrance that are certified by the SPRAVATO Risk Evaluation and Mitigation Strategy (REMS) Program.
Effective treatment
SPRAVATO was proven effective for adults with difficult-to-treat depression when taken with an oral antidepressant.
- In a short-term clinical study of adults with treatment-resistant depression, those who took SPRAVATO and an oral antidepressant experienced a greater reduction of depression symptoms at four weeks (compared to those who received a placebo and an oral antidepressant).
- In a long-term study after 16 weeks of therapy, patients who continued with SPRAVATO therapy were less likely to experience a return of depressive symptoms than those who stopped therapy.
SPRAVATO can be used in combination with transcranial magnetic stimulation (TMS) therapy, counseling, and psychiatric care.
It is not for individuals who are pregnant or who are planning to become pregnant and people who have a history of aneurysm or hemorrhage. SPRAVATO also may not be indicated for individuals with uncontrolled hypertension.